[ad_1]
Sugar.IQ Insights is considered useful and allows users to avoid diabetes-related events up to four hours in advance
DUBLIN and SAN FRANCISCO – June 10, 2019 – Medtronic plc (NYSE: MDT), a global leader in medical technology, today announced real-world data on its Guardian (TM) Connect Continuous Glucose Monitoring System and the Sugar.IQ Diabetes Assistant App. MC)th Scientific Sessions of the Annual Meeting of the American Diabetes Association (ADA) in San Francisco.
The data presented was recorded by Guardian Connect users, badociated with Sugar.IQ Diabete badistant, a distinct and unique smart app that constantly badyzes how an individual's blood glucose levels respond to food intake, dosages insulin, to other factors1. The Sugar.IQ application combines the Guardian Connect system data with artificial intelligence technology from IBM, Medtronic's strategic partner.® Watson Health, to detect trends and important trends in people with diabetes and help them make more informed decisions about how to better manage glucose levels and stay within the target range. The Guardian Connect system and the Sugar.IQ app allow users multiple daily injections (MDI) to manage their diabetes more proactively with personalized and meaningful information.
The data revealed that people using the Guardian Connect system with the Sugar.IQ application had a 4.1% (63.4%) higher idle time compared to Guardian Connect alone (59%). , 3%), which is approximately an additional hour per day. In addition, those who also used the optional Glycemic Assist feature to examine their response to specific foods increased by 4% their duration of immersion in the range compared to those who did not use this feature. Time in Range is the percentage of time people with diabetes spend in the optimal glycemic range of 70 to 180 mg / dL. Each change of 4% in the time range represents a variation of about 0.3% of the A1C.2. The goal of diabetes management is to increase the time spent in this target range and to minimize low and high glucose levels. The study found that Sugar.IQ users found this information helpful in managing their diabetes 91% of times.
The study, which collected data from more than 3,100 diabetics who used the Guardian Connect system for at least five days, also found that the system's overall predictive alerts nearly doubled the patient's low glucose levels. sensor and four times those of the sensor. compared to those who do not use Sugar.IQ. Avoiding the most frequent episodes is a crucial aspect of diabetes management. These data were shared during a poster presentation on "The Real Performance of the Guardian Connect System with Sugar.IQ" by Siddharth Arunachalam.
"Sugar.IQ is the first application to use machine learning to detect blood sugar patterns to notify in advance the serious and elevated events badociated with diabetes," said Michael Hill, vice president and general manager. of the Division Multiple Daily Injection Solutions. part of the diabetes group at Medtronic. "These findings suggest that the Sugar.IQ Diabetes Assistant, in conjunction with our Guardian Connect system, can help patients better understand glucose trends and increase their lifespan, contributing to a change in behavior that is likely to occur." Improve the clinical results. "
In addition to these results, IBM Watson Health shared information on its predictive model during its oral presentation, "Automatic Learning to Predict Hypoglycemic Events from Continuous Glucose Monitoring Data," on Monday, June 10, 2019 at 14:30. PDT. The model was formed on anonymized CGM data from over 10,000 MiniMed (TM) 530G users and Guardian Connect, representing more than 10 million patient-hours. In this historical data badysis, machine learning models were 90% accurate in predicting hypoglycemic events within two hours and 85% in four-hour forecasts. This forecasting technique is part of the new IQcast (TM) Sugar.IQ app feature that uses artificial intelligence technology and real-time dynamic data to predict the likelihood that a person will experience a low event. glucose level in an interval of one to four hours.
Sugar.IQ and Guardian Connect applications are available for iOS-based mobile devices in the United States.
Time in the beach
Time in Range is the percentage of time people with diabetes spend in the optimal glycemic range of 70 to 180 mg / dL. The goal of diabetes management is to increase the time spent in this target range and to minimize high and low sugar levels, which can lead to immediate and long-term complications, such as lesions. blood vessels, which increases the risk of coronary heart disease and stroke. . Damage to the blood vessels can also lead to vision loss, kidney disease and nerve damage.
About the Medtronic Diabetes Group (Www.medtronicdiabetes.com)
Medtronic is working with the global community to change the way people manage diabetes. The company's goal is to transform diabetes care by expanding access, integrating care and improving outcomes so that people with diabetes can enjoy greater freedom and freedom from diabetes. better health.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is one of the world's leading technology, services and medical solutions companies – relieving pain, restoring health and extending the lives of millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company focuses on working with stakeholders around the world to improve health care together.
All forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports in the Securities and Exchange Commission. Actual results may differ materially from the expected results.
-end-
1 Based on information provided by the user.
2 Vigersky RA. Diab Tech Ther.2019; 21: 81-85
contacts:
Pamela Reese
Public relations
+ 1-818-576-3398
Ryan Weispfenning
Investor Relations
+ 1-763-505-4626
Source link
